Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.

Moye-Holz D, van Dijk JP, Reijneveld SA, Hogerzeil HV.

Global Health. 2017 Aug 1;13(1):53. doi: 10.1186/s12992-017-0281-1.

2.

Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.

Chama Borges Luz T, Garcia Serpa Osorio-de-Castro C, Magarinos-Torres R, Wettermark B.

PLoS One. 2017 Apr 7;12(4):e0174616. doi: 10.1371/journal.pone.0174616. eCollection 2017.

3.

Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.

Sagaon-Teyssier L, Singh S, Dongmo-Nguimfack B, Moatti JP.

J Int AIDS Soc. 2016 Oct 19;19(1):20619. doi: 10.7448/IAS.19.1.20619. eCollection 2016.

4.
5.

Could patents interfere with the development of a cardiovascular polypill?

Beall RF, Schwalm JD, Huffman MD, McCready T, Yusuf S, Attaran A.

J Transl Med. 2016 Aug 18;14(1):242. doi: 10.1186/s12967-016-0997-3.

6.

The global intellectual property ecosystem for insulin and its public health implications: an observational study.

Kaplan WA, Beall RF.

J Pharm Policy Pract. 2016 Jul 19;10:3. doi: 10.1186/s40545-016-0072-8. eCollection 2017.

7.

Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.

Chaves GC, Hasenclever L, Osorio-de-Castro CG, Oliveira MA.

Rev Saude Publica. 2015;49. pii: S0034-89102015000100309. doi: 10.1590/S0034-8910.2015049005459. Epub 2016 Jan 15. English, Portuguese. Erratum in: Rev Saude Publica. 2016;50:86err.

8.

The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.

Dutta A, Barker C, Kallarakal A.

PLoS Med. 2015 Nov 24;12(11):e1001907; discussion e1001907. doi: 10.1371/journal.pmed.1001907. eCollection 2015 Nov.

9.

Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.

Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, Crabtree-Ramírez BE, Luz PM, Grinsztejn B, Cesar C, Cahn P, Cortés C, Wolff M, Pape JW, Padgett D, Gotuzzo E, McGowan C, Sierra-Madero JG; CCASAnet.

Bull World Health Organ. 2015 Aug 1;93(8):529-39. doi: 10.2471/BLT.14.147447. Epub 2015 May 27.

11.

Pharmacoeconomics guidelines: The need of hour for India.

Oberoi SS, Oberoi A.

Int J Pharm Investig. 2014 Jul;4(3):109-11. doi: 10.4103/2230-973X.138338. Review.

12.

The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling.

Yu W, Li C, Fu X, Cui Z, Liu X, Fan L, Zhang G, Ma J.

PLoS One. 2014 Jul 23;9(7):e102872. doi: 10.1371/journal.pone.0102872. eCollection 2014.

13.

Enhancing medicine price transparency through price information mechanisms.

Hinsch M, Kaddar M, Schmitt S.

Global Health. 2014 May 8;10:34. doi: 10.1186/1744-8603-10-34.

14.

Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

Danzon PM, Mulcahy AW, Towse AK.

Health Econ. 2015 Feb;24(2):238-52. doi: 10.1002/hec.3013. Epub 2013 Nov 20.

15.

The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis.

Kaplan WA, Wirtz VJ, Stephens P.

PLoS One. 2013 Sep 30;8(9):e74399. doi: 10.1371/journal.pone.0074399. eCollection 2013.

17.

Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.

Stringer JS, Mwango AJ, Giganti MJ, Mulenga L, Levy JW, Stringer EM, Mulenga P, Saag MS, Musonda P, Williams FB, Reid SE, Chi BH.

Int J Epidemiol. 2012 Apr;41(2):448-59. doi: 10.1093/ije/dys022.

18.

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

Moon S, Jambert E, Childs M, von Schoen-Angerer T.

Global Health. 2011 Oct 12;7:39. doi: 10.1186/1744-8603-7-39.

19.

Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.

Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoeper K, Horst HA, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink HJ, Hamouda O, Bartmeyer B; ClinSurv Study Group.

PLoS One. 2011;6(9):e23946. doi: 10.1371/journal.pone.0023946. Epub 2011 Sep 9.

20.

Assessing the population health impact of market interventions to improve access to antiretroviral treatment.

Bärnighausen T, Kyle M, Salomon JA, Waning B.

Health Policy Plan. 2012 Sep;27(6):467-76. doi: 10.1093/heapol/czr058. Epub 2011 Sep 13.

Supplemental Content

Support Center